A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD). Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose […]
Your story can help the Prevent Blindness organization improve vision treatment. Has your eye doctor prescribed a medication or a treatment to address your eye health condition? If so, have you ever found that your insurance company requires you to first try a generally cheaper and possibly less effective drug before they will approve the one […]
New research published this week in Clinical Epigenetics, has identified two new genes linked to the development of age-related macular degeneration (AMD). Led by Dr. Louise Porter at the University of Liverpool, the team identified genes that may become new targets for treatments. 44 human donor eyes were profiled for levels of DNA methylation (a […]
Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage […]